The sports world is becoming increasingly enamoured with CBD.
US professional golfers have become the latest sporting personalities to endorse CBD products, including 2009 US Open winner Lucas Glover.
Glover is reportedly a daily user of a mix of CBD products, including sleeping tablets. He endorses the product Medterra CBD, which is also endorsed by PGA tour professionals Morgan Hoffmann and Charley Hoffman.
Charley Hoffman attributes the use of CBD on the tours to its ability to relieve anxiety, and manage pain from ongoing injuries. It’s also believed to aid recovery after the long periods of exertion. “CBD products help get my energy up, stay alert and focused round after round,” Hoffman said.
But golf is only the latest in a line of sports whose participants have become interested in CBD.
Earlier this year, CBD-Intel reported on Canadian cannabis companies ICC International Cannabis Corp and Organic Flower Investments Group entering into agreements with professional rugby league team Toronto Wolfpack to create sports-focused CBD performance products.
Meanwhile, rival Canadian cannabis firm Canopy Growth has teamed up with medical research body NEEKA Health Canada and The National Hockey League Alumni Association to investigate how CBD treatment affects concussion-related disorders.
CBD-Intel also reported on Aurora Cannabis’s collaboration with Ultimate Fighting Championship (UFC). UFC is a Las Vegas-based mixed martial arts promotions company that will be taking part in studies of CBD’s possible usefulness in treating pain and inflammation, and in recovery and wellbeing.
Heading south of the border to the US, the National Football League and the National Football Players Association announced two committees that will look into pain management and mental health. It will also review team policies concerning prescription medication and require the appointment of a qualified pain specialist for each team.
Will CBD continue to wind its way into the professional sporting arena in the US and Canada – and even further afield? Subscribers to CBD-Intel can keep up to date with news, plus regulatory and market developments in this exciting and ever-changing landscape. Start your free trial now to stay in the picture or enquire about subscription packages and pricing.
– Lorraine Mullaney CBD-Intel contributing writer
Image: cherylvb/Adobe Stock
CBD-Intel does not provide legal, strategic or investment advice. Tamarind Media Limited, the publisher of CBD-Intel, does not accept any liability or responsibility for information or views published.